Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-01-05 | Oral Session 1: Topic Highlights | ETA2022

Sarcopenia as a prognostic factor in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors

Dalmiglio Cristina , Brilli Lucia , Ciuoli Cristina , Sannino Ida , Maino Fabio , Valerio Laura , Cartocci Alessandra , Grazia Castagna Maria

Objective: Recent studies have shown that sarcopenia at cancer diagnosis is associated with a poor survival in patients with solid tumors. Up to now, few data are available among patients with advanced thyroid cancer, especially those treated with tyrosine kinase inhibitors (TKI). We retrospectively evaluated sarcopenia by Skeletal Muscle Index (SMI) in a cohort of advanced thyroid cancer patients before and during TKI treatment and investigated its association with treatment ...

ea0084op-09-44 | Oral Session 9: Thyroid Cancer Clinical | ETA2022

Dynamic risk stratification in long-term clinical outcome of papillary thyroid cancer patients

Valerio Laura , Maino Fabio , Dalmiglio Cristina , Brilli Lucia , Botte Monica , Dalmazio Gilda , Di Stefano Leonardo , Grazia Castagna Maria

Introduction and Objective: The initial assessment of differentiated thyroid cancer (DTC) patients is based on the American Thyroid Association (ATA) risk stratification criteria. Dynamic risk stratification (DRS) of DTC patients takes into consideration the response to initial treatment being reassessed at 1–2 years and revealed significant shifts in the risk categories of DTC patients. We aimed to evaluate the long-term outcome of papillary thyroid cancer (PTC) patients...

ea0092ps3-29-05 | Treatment 2 | ETA2023

Tailored mortality risk in stage I-II DTC patients by integrating ata stratification and response to initial therapy

Dalmiglio Cristina , Forleo Raffaella , Fralassi Noemi , Maino Fabio , Brilli Lucia , Valerio Laura , Trimarchi Andrea , Pilli Tania , Cartocci Alessandra , Grazia Castagna Maria

Objectives: AJCC/TNM staging system provides an estimate of mortality risk in differentiated thyroid cancer (DTC) patients and recent evidence showed that ATA risk stratification may improve the definition of this risk. We speculated that the integration of the response to the initial therapy (RIT) could better define the mortality risk.Methods: We retrospectively evaluated 891 consecutive DTC patients followed at the Section of Endocrinology, University...